

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representation of
The original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

TENT COOPERATION TRE Y

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
United States Patent and Trademark
Office
Box PCT
Washington, D.C.20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 18 April 2000 (18.04.00)	
International application No. PCT/IL99/00447	Applicant's or agent's file reference 119434.9 MM
International filing date (day/month/year) 19 August 1999 (19.08.99)	Priority date (day/month/year) 21 August 1998 (21.08.98)
Applicant FISH, Falk	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:
20 March 2000 (20.03.00)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was

☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

<p>The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland</p> <p>Facsimile No.: (41-22) 740.14.35</p>	<p>Authorized officer S. Mafla</p> <p>Telephone No.: (41-22) 338.83.38</p>
--	--

TENT COOPERATION TRE Y

PCT

NOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

From the INTERNATIONAL BUREAU

To:

REINHOLD COHN AND PARTNERS
P.O. Box 4060
61040 Tel Aviv
ISRAËL

Date of mailing (day/month/year) 04 April 2000 (04.04.00)	IMPORTANT NOTIFICATION
Applicant's or agent's file reference 119434.9 MM	
International application No. PCT/IL99/00447	International filing date (day/month/year) 19 August 1999 (19.08.99)

1. The following indications appeared on record concerning:

☒ the applicant

 ☒ the inventor

 ☐ the agent

 ☐ the common representative

Name and Address

FISH, Falk
4 Dresner Street
69497 Tel Aviv
Israel

State of Nationality

IL

State of Residence

IL

Telephone No.

Facsimile No.

Teleprinter No.

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☐ the person

 ☐ the name

 ☒ the address

 ☐ the nationality

 ☐ the residence

Name and Address

FISH, Falk
4, Eliahu Hakim Street
Appt. 12
69120 Tel Aviv
Israel

State of Nationality

IL

State of Residence

IL

Telephone No.

Facsimile No.

Teleprinter No.

3. Further observations, if necessary:

4. A copy of this notification has been sent to:

<input checked="" type="checkbox"/> the receiving Office	<input checked="" type="checkbox"/> the designated Offices concerned
<input type="checkbox"/> the International Searching Authority	<input type="checkbox"/> the elected Offices concerned
<input type="checkbox"/> the International Preliminary Examining Authority	<input type="checkbox"/> other:

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

Ting Zhao

Telephone No.: (41-22) 338.83.38

**COURTESY COPY OF THE
INTERNATIONAL PRELIMINARY
EXAMINATION REPORT WITH ANNEXES
CONTAINING CLAIMS 1-12 TO REPLACE
THE ORIGINAL CLAIMS FOR
EXAMINATION IN THIS CASE**

**COURTESY COPY OF THE
PCT APPLICATION AS
PUBLISHED WITH
ABSTRACT**

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

nik

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : G01N 33/50, 33/66, 33/72	A1	(11) International Publication Number: WO 00/11469 (43) International Publication Date: 2 March 2000 (02.03.00)
(21) International Application Number: PCT/IL99/00447 (22) International Filing Date: 19 August 1999 (19.08.99) (30) Priority Data: 125880 21 August 1998 (21.08.98) IL (71)(72) Applicant and Inventor: FISH, Falk (IL/IL); 4 Dresner Street, 69497 Tel Aviv (IL). (74) Agent: REINHOLD COHN AND PARTNERS; P.O. Box 4060, 61040 Tel Aviv (IL).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>With amended claims.</i>
(54) Title: METHOD AND KIT FOR THE DETERMINATION OF ANALYTE CONCENTRATION IN BLOOD (57) Abstract A method is provided for determining the level of an analyte in the blood of an individual based on determination of the level of the same analyte in a non-blood sample (e.g. urine, saliva and hair) obtained from the individual. The non-blood sample contains red blood cells and the volume of the blood in the sample together with the amount of the analyte in the sample are the basis for calculating the level of the analyte in the individual's blood. Kits for carrying out the above method are also provided.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

METHOD AND KIT FOR THE DETERMINATION OF ANALYTE CONCENTRATION IN BLOOD

FIELD OF THE INVENTION

This invention concerns a method for determining the concentration of various analytes in the blood of an individual and kits for carrying out the method of the invention.

5

PRIOR ART

The following is a list of prior art publications referred to in the present specification:

- 10 1. Guy and Rao, U.S. Patent 5,362,307.
2. Sönsken PH, *Acta Endocrinol. Suppl.* (Copenhagen) **238**:145-155 (1980).
- 15 3. Patrick, A.W., *et al.*, *Diabet. Med.*, **11**:62-65 (1994).
4. Forbat, L.N., *et al.*, *J.R. Soc. Med.*, **74**:725-728 (1981).
5. Ben-Aryeh, H., *et al.*, *J. Diabet. Complications*, **2**:96-99 ((1988).
- 20 6. PCT Application Publication No. WO 99/22639
7. Song, S.J. *Forensic Sci. Int.*, **36**:173-7 (1988).
- 25 8. Keating, S.M., Allard, J.E., *Med. Sci. Law*, **34**:187-201 (1994).
9. Akbarov, Z.S., Rakhimova, Russian Patent No. 2064681.

10. Geigy Scientific Tables, 8th Edition, Ciba-Geigy Publication, Basle, Switzerland, ISBN 0-914168-50-9 (1980).
11. Kimes, D.R., *et al.*, *J. Forensic Sci.*, **29**:64-66 (1984)
12. Sakita, S., *et al.*, *Dermatol. Sci.*, 7 Suppl: S1-4 (1994).
13. U.S. Patent No. 5,268,148.

The acknowledgement herein of the above art should not be construed as an indication that this art is in any way relevant to the patentability of the invention as defined in the appended claims.

The above publications will be acknowledged in the following by indicating their number from the above list.

BACKGROUND OF THE INVENTION

There are many circumstances in which it is necessary to determine the level of one or more analytes in the blood of an individual at a given point in time. Often, a low volume blood sample extracted from the individual is sufficient for obtaining the required information. Such low volume blood samples are especially suitable in conditions wherein it is necessary to obtain a blood sample from the individual frequently, such as in the case of diabetic patients. Several years ago, a ten year long diabetes care and complications trial (DCCT) showed that the preferred mode of treatment of insulin dependent diabetes (Type 1) was by frequent small-dose administrations of insulin to such patients and determining the glucose level after each such administration. To follow such a treatment, a diabetic patient is required to puncture his skin and obtain a drop of blood for the glucose test at least three times a day. Such a frequent and repetitive puncturing is painful and often results in infection and formation of hard scar tissue and as a result, many diabetic patients neglect to sufficiently test their glucose level.

In an attempt to minimize the harm or pain caused by various techniques routinely used for obtaining a body fluid, several minimally invasive or non-invasive methods for determining the concentration of a substance in the blood by obtaining and analyzing a body fluid have been developed in which a very small sample of body fluid is obtained. Guy and Rao⁽¹⁾ have shown a method for determining the concentration of an inorganic or organic substance in an individual by obtaining an interstitial fluid sample from the individual by a process called iontophoresis. In accordance with this method, an electric field is employed which causes migration of ions which carry with them non-charged molecules, e.g. glucose.

Another minimally invasive method for obtaining a body fluid is that of SpecRx, Inc. Norcross, GA, USA. A minute and shallow round hole is created in the skin, extending just below the stratum corneum and a sample of interstitial fluid is collected through this hole. That fluid is then tested for its glucose content by one of the methods known in the art.

In such minimally invasive methods the concentration of the tested substance in the obtained interstitial fluid sample often does not correctly indicate the level of the same substance in the blood of the tested individual at the time in which the sample was obtained or shortly thereafter. This is mostly due to the fact that the concentration of the tested substance varies in different locations in the body and at different hours of the day, and therefore, the concentration of a certain analyte in a body fluid other than the blood itself may significantly differ from its concentration in the blood at the same time. Moreover, although the side effects of such minimally invasive methods are reduced in comparison to some conventional methods for obtaining a blood sample, they still often result in discomfort to the tested individual, and involve wounding of the skin, and in some cases even disruption of blood vessels.

Attempts to detect the correct glucose level in the blood by determining the level of glucose in fluids of body samples other than blood

such as saliva, urine or tears were found to be non suitable since the concentration of the glucose in such fluids was shown to be variable and, more often than not, did not directly reflect the concentration of the glucose in the blood at the relevant point in time⁽²⁻⁶⁾.

5 Hair has also been used to detect the existence of various substances in a tested individual. The detection of a certain substance in the hair, obtained from an individual, provides evidence and information on the existence of the same substance in the tested individual at a certain, unknown period of time, i.e. that the individual was exposed at some time or another to
10 the substance. Methods based on analysis of hair have been used, for example, in forensic medicine to determine whether an individual has, some time in the past, been exposed to drugs, for determining ABO blood groupings⁽⁷⁾ (e.g. as evidence in cases of sexual assaults⁽⁸⁾) etc.

 The percent of protein glycation (i.e. binding of glucose to
15 protein) in hair specimens has also been used to obtain information on the tested individual from which the hair specimen was obtained. The growth rate of hair is relatively high and therefore it is possible to compare the level of glycated protein in the older part of the hair closer to the level of the glycated protein in the newer part of the hair (closer to the root). A higher level of
20 glycated protein in the newer part of the hair may, in some cases, indicate the development of a certain condition in an individual e.g. to predict the possible onset of diabetes⁽⁹⁾.

 All the above methods provide general information which enables to determine whether a tested individual was ever exposed to a
25 substance of interest. Such methods have not been used for determining the level of a desired substance in the blood of the tested individual at the time in which the hair was obtained.

 It has been shown that some of the above mentioned body samples, including urine, saliva or hair roots contain red blood cells⁽¹⁰⁻¹²⁾.

SUMMARY OF THE INVENTION

In accordance with the present invention, it has been realized that it may be possible to determine the concentration of various analytes in an individual's blood by obtaining a sample from the individual which is a non-blood sample but which contains within it red blood cells and determining the concentration of the analyte in the blood or blood cells present in such a sample. In accordance with the invention it was realized for the first time that such samples are a readily available source for blood or red blood cells which may be useful in determining the level of analytes of interest in the blood of an individual.

The concentration of various analytes, and specifically of glucose, in the red blood cell is lower than their concentrations in the plasma, however, it is always at a constant ratio to the concentration of the analyte in the plasma. Therefore, by determining the concentration of glucose or any other analyte in the red blood cells present in the non-blood body samples, it is possible to calculate and determine the concentrations of the measured analyte in the blood of the individual from which these samples were obtained.

By its first aspect, the present invention thus provides a method for determining the level of an analyte in the blood of an individual comprising:

- (i) obtaining a sample from said individual, said sample being a non-blood sample but containing blood components;
- (ii) determining the volume of blood in the obtained sample by measuring the level of a blood component in said samples;
- (iii) determining the amount of said analyte in the sample or in the blood cells present in said non-blood sample; and
- (iv) calculating the level of said analyte in the blood of the tested individual based on the measurements in (ii) and (iii).

The term "*level*" as it is to be understood in the context of the present invention relates either to a quantity or to the concentration of the tested analyte.

5 An analyte may be any substance or component found in the blood for example, sugars, proteins, organic compounds etc., which is present in detectable amounts in the non-blood fluid or sample.

The volume of blood in the obtained body or sample is measured as a basis for calculating the concentration of the analyte in the blood. Measurement of the blood volume is based on determining the amount
10 of a blood component in the sample.

The term "sample" relates to any fluid or non-fluid (e.g. tissue or cells) which is obtained from an individual and which contains within it red blood cells.

Preferably, the non-blood sample is obtained by non-invasive or
15 minimally invasive methods. The terms "*non-invasively*" or "*minimally invasive*" relate to any method for obtaining a body fluid sample which does not involve penetration of the inner layers of the skin of the individual with a sharp tool or with evaporating radiation (e.g. laser irradiation).

By a preferred embodiment of the invention, the volume of the
20 blood will be determined by measuring the amount of hemoglobin in the obtained sample by any of the methods known in the art (e.g. Piazza *et al.*, *Boll Soc. Ital. Biol. Sper* 67:1047-1052, 1991; Piazza *et al.*, *JAMA* 261:244-245, 1989). Examples of such methods are methods relying on the peroxidase activity of hemoglobin which incorporate a chromogenic or luminescent signal
25 imparting high sensitivity (see Example 2 below). Hemoglobin in body samples can also be detected and quantified by commercially available dry chemistry test strips, which rely on colorimetric reaction of hemoglobin with peroxides, such as those described in U.S. Patents 4,615,982, 3,975,161 and 4,017,261, assigned to Lachema a.s., Brno, Czech Republic and in U.S. Patent

No. 5,089,420 assigned to Miles, Elkhart, IN, USA. Other methods for determining the level of hemoglobin may involve Drabkin's Reagent (e.g. per Sigma Chemical Co. Cat # 525-A). The volume of blood present in the obtained sample may also be determined on the basis of the measured level of any other blood component such as those mentioned above.

The amount of the tested analyte in the obtained sample is determined using any of the methods known in the art which are suitable for determining the level of the specific analyte to be tested. By a preferred embodiment of the invention the tested analyte is glucose. The level of the glucose in the body sample may be determined using any of the known highly sensitive glucose determination methods based on fluorescence, chemiluminescence, or bioluminescence. Examples of such methods are continuous monitoring of reactions that produce NADH and NADPH using immobilized luciferase and oxido reductases from *Beneckea harveyi* (Haggerty, C. *et al.*, *Anal. Biochem.*, **88**:162-173, 1978 or Jablonski, E., *et al.*, *Clin. Chem.*, **25**:1622-1627, 1979). In addition, any of the colorimetric or electrochemical methods known in the art which utilize glucose oxidase or glucose dehydrogenase or hexokinase may also be used for determining the level of the glucose in the sample (see for example Sigma Cat #: 315, 115-A, 510-A).

Calculation of the concentration of the tested analyte is based on the ratio of the concentration of the analyte which was measured in the obtained sample to the concentration of the blood component measured in the same sample and the average content of the same blood component in human blood. For example, wherein the tested analyte is glucose and the measured blood component is hemoglobin, the glucose concentration in the blood of the tested individual is calculated from the ratio of the glucose to hemoglobin which was measured in the obtained sample and the average hemoglobin contents in human blood.

The amount of the analyte in the blood of the tested individual will be calculated on the basis of the measurements of the blood volume and the level of the tested analyte in the obtained sample. Calibration values of the blood component and the tested analyte will typically be obtained from testing diluted standard solutions of these components by methods known in the art such as those described in the examples below. Typically, this will be carried out by dividing a body sample obtained from a tested individual into several aliquots; some being tested for the level of the tested analyte (e.g. glucose) by one or more of the tests known in the art and the remaining aliquots being tested for the level of the same analyte using the method of the invention. The results obtained by using the known methods and the results obtained by using the method of the invention are then correlated by using a standard regression analysis from which a regression equation having the following structure is obtained:

15

$$\text{level of tested analyte in the blood} = (\text{the level of the tested analyte measured by the method of the invention}) \times (\text{slope}) + (\text{intercept});$$

wherein the slope and intercept values are derived from the regression analysis. Regression analysis can be easily performed by methods known in the art using software known to a person versed in the art such as, for example, Excel (Microsoft Corporation, Redmond, WA), Lotus 123, Quattro Pro, etc. Statistical software packages are also available such as, for example, the SPSS Program. In addition, regression functions are also incorporated into various hand-held calculators such as, for example, those manufactured by Texas Instruments, U.S.A., Hewlett-Packard, U.S.A., Casio, Japan, Sharp, Japan, etc.

25

By one embodiment of this aspect of the invention the non-blood body sample obtained from an individual to be tested is urine or saliva, which contain red blood cells and which comprise various analytes in their sap

including detectable amounts of glucose. The obtaining of samples of urine and saliva does not inflict any harm to the tested individual and prevents the possible adverse side effects mentioned above. Thus such samples may be frequently and repetitively obtained without causing harm to the individual.

5 Wherein the obtained body samples are readily available body fluids such as blood or saliva, the tested analyte may originate from two sources: (a) fluid secreted by a gland or tissue or (b) from blood which contaminates the fluids in the samples. Therefore, in such cases, in order to determine the level of the tested analyte in the blood of the tested individual
10 (e.g. glucose), the intercellular level of the tested analyte in the red blood cells present in the sample is measured. The amount of the blood component (typically hemoglobin), in the sample is also measured and both are used as a basis for determining the volume of the red blood cellular fluid.

 In order to determine the level of the tested analyte in the
15 obtained urine or saliva sample as well as the amount of the blood component in the sample, typically, the red blood cells present in the obtained samples are first separated.

 Separation of the red blood cells from the obtained sample may be carried out by any of the methods known in the art such as centrifugation, or
20 filtration. Alternatively, the samples may be applied onto a filter designed to trap red cells. Several non-limiting examples of such filters are the PlasmaSep™, filter obtained from Whatman®, Fairfield, NJ, U.S.A., the CytoSep® filter obtained from Ahlstrom Filtration, Mt. Holly Springs, PA, U.S.A. or the HemaSep® filter obtained from Pall, East Hills, NY, USA. The
25 trapped red cells are then tested for the level of the analyte and blood component. Optionally, the red cells may be lysed before testing for their contents. Some of these methods are described in the examples below but should not be construed as limiting.

Before separation of the red blood cells, an agglutinating agent such as, for example, wheat germ agglutinin may be added to the sample which causes agglutination of the red blood cells which may then be separated by any of the abovementioned methods. The intracellular level of the tested analyte will then be determined in the red blood cell. In accordance with one
5 embodiment the separated red blood cells will first undergo a lysis step in order to release their contents.

Although, in most cases, it is preferred to first separate the red blood cells from the sample, at times, it may be preferred to lyse the cells without first separating them. In such a case, the sample will be divided into
10 two specimens. To the first specimen, a lysis agent will be added which will cause lysis of the red blood cells whose contents will spill into the specimen. By subtracting the measured concentration of the tested analyte in the second specimen to which a lysis agent was not added, from the measured
15 concentration of the analyte in the first specimen in which the red blood cells were lysed, it will be possible to determine the intracellular concentration of the analyte in the red blood cells (see sample 3 below).

Typically, a lysis agent will be added to the body sample at one of the stages of the method of the invention, but, at times, it may be possible to
20 determine the intracellular concentration of the analyte in the red blood cells present in the sample without addition of a lysis agent. For example, wherein the sample is first run through a filter, the fixation of the cells onto the filter may cause ruptures in the cell membrane of the red blood cells and as a result their content may flow out of the cells and the level of the tested analyte is then
25 determined.

Lysis of the red blood cells present in the samples may be carried out by any of the methods known in the art using known red cell lysing agents such as for example, saponin, ammonium salts, various detergents, hypotonic solutions, snake venoms, etc.

In accordance with this embodiment of the invention, the present invention provides a method for determining the level of an analyte in the blood of an individual comprising:

- (i) obtaining a urine or saliva sample from said individual;
- 5 (ii) measuring the level of said analyte in the red blood cells present in said sample;
- (iii) measuring the amount of a blood component in the red blood cells in said sample and on the basis of this measurement calculating the volume of blood cells or number of blood cells in
10 said samples; and
- (iv) calculating the level of said analyte in the blood of the tested individual based on the measurements in (ii) and (iii).

Wherein the body sample is saliva, it is possible, prior to obtaining the sample to use means which stimulate blood flow into the saliva
15 such as swabs, brushes, toothpicks or various foods. In addition, in obtained saliva samples, before beginning measurements of the various substances in the obtained sample, it may be, at times, advantageous to remove or breakdown mucinaceous materials present in the sample by one of the methods described in the art¹ (such as, for example, U.S. Patent No. 5,268,148).

20 The term "saliva" encompasses, in accordance with the invention, *inter alia*, saliva, diluted saliva, fluid obtained from the mouth cavity or from the skin surrounding the mouth cavity, scrapings attached from the surface of the mouth cavity, exudates or transudates obtained from the mouth cavity, and expectorated or drawn mouthwash obtained from the mouth cavity.

25 By a preferred embodiment of the invention, the above method will contain an additional step wherein the red blood cells are first separated from the sample by any of the methods described above. By another preferred embodiment, the method will comprise an additional step wherein a lysing

agent will be added to the sample before the amount of the blood component and tested analyte are measured.

In accordance with an additional aspect of the invention the obtained body sample is hair roots.

5 According to the invention, it has been realized that there is a readily available naturally obtainable and sufficient source of fresh capillary blood in a hair root sample which may be used for determining the level of a tested analyte in the hair root as a basis for determining its level in the blood of the individual from which the hair roots were obtained. The hair follicle
10 includes an extensive network of blood vessels which provide nourishment to the rapidly dividing hair root cells. A complex of entwined blood capillaries (papilla) enters the wide hair root at the bottom end of the hair and when the hair is plucked the blood rich papilla and sometimes the whole or part of the follicle's sheath is still attached to the hair shaft, thus providing a specimen of
15 capillary blood. The capillary blood supply is of blood which reached the hair follicle only recently and therefore the level of the substance in the capillary blood very accurately represents that of the same substance in the individual's blood. Occasionally a tissue sample containing interstitial fluid may also be found on the plucked hair and used as a source for determining the level of an
20 analyte in the blood. Since the interstitial fluid is in close proximity to abundant and active blood vessels of the hair root, the level of the analyte determined in this interstitial fluid is very indicative of the level of the same analyte in the blood at the same time.

Wherein the obtained body sample is hair roots, due to the
25 extensive network of blood vessels in the hair root and hair sheath, it is expected that the whole amount of the tested analyte, e.g. glucose, in such a sample is derived from the fresh blood in the hair root. In addition, the origin of the measured blood component, typically being hemoglobin, in the hair may also be only the blood in the hair root. Since the concentration of the blood

component in the blood of an individual is relatively constant, the concentration of the blood component measured in the fresh blood in the hair root is equal to its concentration in the blood of the tested individual. Therefore, it becomes possible to determine the concentration of the tested
5 analyte (e.g. glucose) in the blood of the tested individual on the basis of the amount of the free analyte and amount of the blood component both extracted from the hair roots.

Contrary to the difficulties caused by repetitive puncturing of the skin, repetitive plucking of hair does not create any wound or scarring and the
10 side effects as well as the individual discomfort are minimal, especially when a small number of hair shafts are being collected. In addition, a large fraction of the hair is naturally shed or easily removed by e.g. combing and such hair may also be obtained for use in accordance with the invention shortly after it is removed.

15 Thus, in accordance with an additional embodiment of this aspect of the invention, the level of a tested analyte in a blood of an individual is determined on the basis of the level of the analyte in a hair sample obtained from said individual. In accordance with this embodiment, the present invention thus provides a method for determining the level of an analyte in the
20 blood of an individual comprising:

- (i) obtaining a sample of hair from said individual;
- (ii) determining the amount of blood or interstitial fluid in said obtained sample and if necessary, correcting variations between different hair samples;
- 25 (iii) determining the level or concentration of said analyte in said blood or interstitial fluid; and
- (iv) calculating the level of said analyte in the blood of the tested individual based on the measurements in (ii) and (iii).

In accordance with this embodiment of the invention, the sample of hair may be obtained by any of a number of methods, e.g. by use of a hair removal instrument, adhesive strips, a forceps, by combing, etc.

Before determining the amount of the blood or interstitial fluid in the hair follicle, these may be extracted from the hair follicle by incubating the
5 the hair follicle, these may be extracted from the hair follicle by incubating the obtained hair in a suitable diluent such as, for example, buffered saline. The diluent may include components which will enhance its extracting capacity, such as, for example, anticoagulants (e.g. heparin, citrate, EDTA), enzymes (e.g. proteases, neuroaminidases), keratolytic agents (benzoic and/or salicylic
10 acids or their salts), and detergents.

The remaining steps of the method of the invention carried out on the hair root specimen will be similar to the steps described above with regards to other kinds of body samples and fluids. However, in this case, a separation step of red blood cells is not necessary since the only origin of the tested
15 analyte is in the blood extracted from the hair root. Notwithstanding the above, it may at times be advantageous to add a lysing agent to the sample extracted from the hair root to facilitate the measurement of the tested analyte and blood component in the sample.

By an additional aspect of the invention, a kit is provided for
20 determining the level of an analyte in the blood of a tested individual comprising:

- (i) means for obtaining a sample from said individual, said sample being a non-blood sample but containing blood components;
- (ii) means for measuring the level of a blood component in the
25 sample;
- (iii) means for measuring the level of the tested analyte in the obtained sample;

- (iv) means for calculating the level of the tested analyte in the blood of the tested individual on the basis of the measurements obtained in (ii) and (iii) above.

By one embodiment of this aspect of the invention, the above kit
5 will also comprise means for separating the red blood cells from the sample, which may be any one of those discussed above. By an additional embodiment, the kit may also comprise means for lysing the red blood cells in the sample such as, for example, any of those detailed above.

The above kit may also comprise a test strip incorporating the
10 reagents or structures necessary to carry out the measurement of the tested analyte as well as the blood component. In such a case, an instrument into which the test strip can be inserted or to which the test strip may be connected is also included in the kit. Such an instrument, which may be portable, is capable of detecting and analyzing the signal emitted by the test strips and
15 optionally may translate them directly into prevalent units.

Wherein the obtained body fluid sample is saliva, the above kit may also include means to stimulate blood flow into the saliva such as swabs, brushes, toothpicks or stimulating pieces of food which are applied to the tested individual before obtaining a body sample. The above kit may then also include
20 reagents and means capable of removing or breaking down the mucinaceous materials present in the saliva (such as those mentioned above) for treating the saliva sample prior to analysis or testing.

Wherein the tested analyte is glucose, the above kit may also comprise a metabolic inhibitor such as, for example, sodium fluoride which is
25 capable of preventing glucose utilization by any living cell contained in the sample.

In accordance with the embodiments of the invention in which the obtained body sample is a hair sample, the kit of the invention will comprise the following:

- (i) a hair removal instrument;
- (ii) a suitable diluent in which the blood or interstitial fluid from the obtained hair is collected;
- (iii) means for the determination of the level of a blood component in the blood or interstitial fluid specimen;
- (iv) means for determination of the level of said analyte in the blood or interstitial fluid specimen; and
- (v) means for calculating the level of the tested analyte in the blood of the tested individual on the basis of the measurements in (iii) and (iv) above.

EXAMPLES

The invention will now be demonstrated by way of the following non-limiting examples.

Example 1 Determination of the level of glucose and hemoglobin in a sample obtained from a hair follicle in accordance with the invention

Obtaining a sample from hair of a tested individual

About 5-10 hair strands are plucked by pulling on any hairy skin area (scalp, hands, legs, face, nose, ears, etc.). The hair is then washed in water and immersed in 500 μ L of Sigma Chemical Co. (St. Louis, MO, USA) red cell lysing agent (Cat # R1129).

The hair is incubated in the above solution for a period of time suitable for obtaining the maximum volume of blood and its interstitial fluid from the hair. The fluid sample is then divided into the following two samples:

- a. A sample used for determining the level of glucose in the obtained blood or interstitial fluid

5 In a micro-centrifuge ("Eppendorf" style) test tube, 25 μL of the above sample is mixed with 100 μL of a glucose oxidase, horseradish peroxidase mix, prepared from the enzyme capsule in Sigma Chemicals colorimetric glucose test kit (cat # 510-A or 510-DA). Following 10 minutes incubation at room temperature (18-30°C), a hundred μL of 1:1 diluted Pierce (Rockford, IL, USA) PowerSignal™ Luminol/Enhancer (derived from cat # 37075) are then added and incubation continued for another 1 minute. The test tube is then inserted into a Labsystems Luminoskan luminometer and the luminescence is recorded.

- 15 b. Sample 2 is used for determining the level of hemoglobin in the blood and interstitial fluid obtained from the hair of the tested individual

In a micro-centrifuge ("Eppendorf" style) test tube, 25 μL of the above sample is mixed with 100 μL of Pierce PowerSignal™ ELISA Chemiluminescent Substrate Working Solution, prepared according to the instructions of product # 37075. Following 1 minute of incubation, the test tube is then inserted into Labsystems Luminoskan luminometer and the luminescence is recorded.

- 25 c. The levels of the glucose and hemoglobin in the sample obtained from the hair of the tested individual is then calculated as follows:

The net glucose reaction is derived from the above glucose luminescence minus the hemoglobin luminescence. The actual glucose and hemoglobin content of the hair sample is calculated employing the calibration equation. The glucose concentration in

the blood is calculated from the ratio of glucose to hemoglobin in the sample and the average hemoglobin contents of human blood.

d. The glucose and hemoglobin values were calibrated as follows:

5 Glucose and hemoglobin calibration values were obtained from testing diluted standard glucose and hemoglobin solutions, employing the above procedures. A calibration equation is derived from the results and employed in the above calculations.

10 **Example 2 Determination of the level of glucose and hemoglobin in a urine or saliva body sample using luminescent method involving centrifugation**

 About 500 μ L of urine or saliva are mixed with 500 μ L of 0.85%
15 saline and centrifuged in a Microfuge (Eppendorf or other) for 5 minutes to spin down the red cells. The supernatant is decanted and the cell sediment is washed in saline and then resuspended in a buffer solution containing a red cell lysing agent or Sigma Chemical Co (St. Louis, Mo. USA) red cell lysing agent (Cat # R 1129).

20 Following the required incubation period, two aliquots are removed. One of the aliquots is subjected to glucose analysis and the other - to hemoglobin analysis.

The level of glucose in the first aliquot is then determined as follows:

25 In a micro-centrifuge ("Eppendorf" style) test tube, 25 μ L of the above sample is mixed with 100 μ L of a glucose oxidase, horseradish peroxidase mix, prepared from the enzyme capsule in Sigma Chemicals colorimetric glucose test kit (Cat # 510-A or 510-DA). Following 10 minutes incubation at room temperature (18-30°C), a hundred μ L of 1:1 diluted Pierce
30 (Rockford, IL, USA) PowerSignal™ Luminol/Enhancer (derived from Cat

37075) are then added and incubation continued for another 1 minute. The test tube is then inserted into a Labsystems Luminoskan luminometer and the luminescence is recorded.

- 5 The level of hemoglobin in the second aliquot is then determined as follows:

 In a micro-centrifuge ("Eppendorf" style) test tube, 25 μ L of the above sample is mixed with 100 μ L of Pierce PowerSignal™ ELISA Chemiluminescent Substrate Working Solution, prepared according to the instructions for product # 37075. Following 1 minute of incubation, the test
10 tube is then inserted into a Labsystems Luminoskan luminometer and the luminescence is recorded.

 Calibration values and calculations are determined as explained in Example 1 above.

15

Example 3 Determination of the level of glucose and hemoglobin in a urine or saliva body sample using the lysis method

 Equal size aliquots are derived from the urine or saliva sample.
20 One of the aliquots is mixed with a reagent, which causes the lysis of red blood cells such as, for example, saponin. Another aliquot is mixed with the same volume of a non-lytic reagent. The levels of glucose and hemoglobin are determined in both aliquots. The amount of glucose and hemoglobin in the red cells sap is obtained by subtracting the values of the non-lysed aliquot from
25 the lysed one.

Example 4 Determination of the level of glucose and hemoglobin in a urine or saliva body sample using the filtration method

Urine or saliva sample is applied to a filter, designed to trap red
5 cells. The sample is sucked through the filter by e.g. application of vacuum or
providing an absorbent pad under the filter (such absorbent materials are very
well known in the art: Polyfiltronics, AFC (American Filtrona Corp). The filter
is then subjected to glucose and hemoglobin tests. The endpoint signal of the
tests can be colorimetric, fluorometric, luminescent, electrochemical,
10 radioactive (non-limitative list of endpoints), all are well known in the art.

In alternative embodiments of the filtration method:

A. The filter can be impregnated with reagents for hemoglobin (e.g. as in
15 urine test strips, supplied by Bayer Corp. (U.S. Patent No. 5,089,420) or
Lachema a.s., Brno, Czech Republic. U.S. Patents 3,975,161 and 4,017,261)
and glucose.

B. Individual red cells can be visualized on the filter (as in the above
20 mentioned urine test strips) and the signal that develops with each cell can be
individually examined e.g. with a microscope and/or camera with macro lens.

CLAIMS:

1. A method for determining the level of an analyte in the blood of an individual comprising:
 - 5 (i) obtaining a sample from said individual, said sample being a non-blood sample but containing blood components;
 - (ii) determining the volume of blood in the obtained sample by measuring the level of a blood component in said samples;
 - (iii) determining the amount of said analyte in the sample or in the
10 blood cells present in said non-blood sample; and
 - (iv) calculating the level of said analyte in the blood of the tested individual based on the measurements in (iii) and (iv).
2. The method of Claim 1, wherein said blood component is hemoglobin.
- 15 3. The method of Claims 1 or 2, wherein said analyte is glucose.
4. A method according to any one of Claims 1-3, wherein said non-blood samples are urine or saliva samples, the method comprising:
 - (i) obtaining a urine or saliva sample from said individual;
 - (ii) measuring the level of said analyte in the red blood cells present
20 in said sample;
 - (iii) measuring the amount of a blood component in the red blood cells in said sample and on the basis of this measurement calculating the volume of blood cells or number of blood cells in said samples; and
 - 25 (iv) calculating the level of said analyte in the blood of the tested individual based on the measurements in (ii) and (iii).
5. A method according to Claim 4, wherein prior to measuring the level of said analyte in the red blood cells, said cells are first separated from the sample.

6. A method according to Claims 4 or 5, wherein a lysing agent capable of lysing said red blood cells is added to said obtained sample.

7. A method according to any one of Claims 4-6, wherein the sample obtained from the individual is a saliva sample.

5 8. A method according to Claim 7, wherein prior to obtaining said saliva sample, means are used to stimulate blood flow into the saliva of the individual from which the sample is obtained.

9. A method according to Claims 7 or 8, wherein means capable of removing or breaking down the mucinaceous materials present in said sample
10 are added to the saliva sample.

10. A method according to Claim 1, wherein said non-blood sample is a sample of hair obtained from said individual, the method comprising:

- (i) obtaining a sample of hair from said individual;
- (ii) determining the amount of blood or interstitial fluid in said
15 obtained sample and if necessary, correcting variations between different hair samples;
- (iii) determining the level or concentration of said analyte in said blood or interstitial fluid and
- (iv) calculating the level of said analyte in the blood of the tested
20 individual based on the measurements in (ii) and (iii).

11. A method according to claim 10 wherein before stage (ii) said blood or interstitial fluid are first extracted from the hair follicle of said obtained hair.

12. A kit for determining the level of an analyte in the blood of a
25 tested individual comprising:

- (i) means for obtaining a sample from said individual, said sample being a non-blood sample but containing blood components;
- (ii) means for measuring the level of a blood component in the sample;

(iii) means for measuring the level of the tested analyte in the obtained sample;

(iv) means for calculating the level of the tested analyte in the blood of the tested individual on the basis of the measurements obtained in (ii) and (iii) above.

5 **13.** A kit according to Claim 12, further comprising means for separating said red blood cells from the sample.

14. A kit according to Claims 12 or 13, further comprising means for lysing said red blood cells.

10 **15.** A kit according to Claim 12, further comprising a test strip incorporating reagents or structures necessary to carry out the measurement of the tested analyte and blood component and a instrument into which the test strip can be inserted into or to which the test strip may be connected; said instrument capable of detecting and analyzing a signal emitted by said test strips and optionally translating said signals into prevalent units.

16. A kit according to Claims 12-15, wherein the obtained body fluid sample is saliva further comprising means for stimulating blood flow into the saliva prior to obtaining of said sample.

20 **17.** A kit according to any one of Claims 12-16, wherein the obtained body fluid sample is saliva, said kit further comprising reagents and means capable of removing or breaking down the mucinaceous materials in said saliva sample.

18. A kit according to Claim 12, wherein the obtained body sample is a hair sample, said kit comprises the following:

- 25 (i) hair removal means;
- (ii) a suitable diluent in which the blood or interstitial fluid from the obtained hair is collected;
- (iii) means for the determination of the level of a blood component in the blood or interstitial fluid specimen;

(iv) means for determination of the level of said analyte in the blood or interstitial fluid specimen; and

(v) means for calculating the level of the tested analyte in the blood of the tested individual on the basis of the measurements obtained in (iii) and (iv) above.

5

19. A kit according to Claims 12-18, wherein the tested analyte is glucose.

20. A kit according to Claim 19, further comprising a metabolic inhibitor capable of preventing glucose utilization by living cells present in said

10

AMENDED CLAIMS

[received by the International Bureau on 13 February 2000 (13.02.00);
original claims 4-9 and 16-17 cancelled; original claims 10-15 and 18-20
renumbered as claims 4-9 and 10-12
other claims unchanged (3 pages)]

1. A method for determining the level of an analyte in the blood of an individual comprising:
 - 5 (i) obtaining a sample from said individual, said sample being a non-blood sample but containing blood components;
 - (ii) determining the volume of blood in the obtained sample by measuring the level of a blood component in said samples;
 - (iii) determining the amount of said analyte in the sample or in the
10 blood cells present in said non-blood sample; and
 - (iv) calculating the level of said analyte in the blood of the tested individual based on the measurements in (iii) and (iv).
2. The method of Claim 1, wherein said blood component is hemoglobin.
- 15 3. The method of Claims 1 or 2, wherein said analyte is glucose.
4. A method according to Claim 1, wherein said non-blood sample is a sample of hair obtained from said individual, the method comprising:
 - (i) obtaining a sample of hair from said individual;
 - (ii) determining the amount of blood or interstitial fluid in said
20 obtained sample and if necessary, correcting variations between different hair samples;
 - (iii) determining the level or concentration of said analyte in said blood or interstitial fluid and
 - (iv) calculating the level of said analyte in the blood of the tested
25 individual based on the measurements in (ii) and (iii).
5. A method according to claim 4 wherein before stage (ii) said blood or interstitial fluid are first extracted from the hair follicle of said obtained hair.
6. A kit for determining the level of an analyte in the blood of a
30 tested individual comprising:

- (i) means for obtaining a sample from said individual, said sample being a non-blood sample but containing blood components;
 - (ii) means for measuring the level of a blood component in the sample;
 - 5 (iii) means for measuring the level of the tested analyte in the obtained sample;
 - (iv) means for calculating the level of the tested analyte in the blood of the tested individual on the basis of the measurements obtained in (ii) and (iii) above.
- 10 7. A kit according to Claim 6, further comprising means for separating said red blood cells from the sample.
8. A kit according to Claims 6 or 7, further comprising means for lysing said red blood cells.
9. A kit according to Claim 6, further comprising a test strip
- 15 incorporating reagents or structures necessary to carry out the measurement of the tested analyte and blood component and a instrument into which the test strip can be inserted into or to which the test strip may be connected; said instrument capable of detecting and analyzing a signal emitted by said test strips and optionally translating said signals into prevalent units..
- 20 10. A kit according to Claim 6, wherein the obtained body sample is a hair sample, said kit comprises the following:
- (i) hair removal means;
 - (ii) a suitable diluent in which the blood or interstitial fluid from the obtained hair is collected;
 - 25 (iii) means for the determination of the level of a blood component in the blood or interstitial fluid specimen;
 - (iv) means for determination of the level of said analyte in the blood or interstitial fluid specimen; and
 - (v) means for calculating the level of the tested analyte in the blood
 - 30 of the tested individual on the basis of the measurements obtained in (iii) and (iv) above.

11. A kit according to Claims 6-10, wherein the tested analyte is glucose.

12. A kit according to Claim 11, further comprising a metabolic inhibitor capable of preventing glucose utilization by living cells present in said
5 sample.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 119434.9 MM	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/IL99/00447	International filing date (day/month/year) 19/08/1999	Priority date (day/month/year) 21/08/1998
International Patent Classification (IPC) or national classification and IPC G01N33/50		
Applicant FISH, Falk		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.



2. This REPORT consists of a total of 5 sheets, including this cover sheet.

- ☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 3 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand 20/03/2000	Date of completion of this report 19.10.2000
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Hoesel, H Telephone No. +49 89 2399 8693 

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/IL99/00447

I. Basis of the report

1. This report has been drawn on the basis of *(substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.)*:

Description, pages:

1-20 as originally filed

Claims, No.:

1-12 with telefax of 20/03/2000

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	1 - 12
	No:	Claims	
Inventive step (IS)	Yes:	Claims	1 - 12
	No:	Claims	
Industrial applicability (IA)	Yes:	Claims	1 - 12
	No:	Claims	

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/IL99/00447

2. Citations and explanations

see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

SECTION V:

1. The present assay method relies upon the finding that residual blood cells are contained in non-blood samples, and that the amount of analyte measured in these residual cells contained in a non-blood sample reflects the actual concentration of the analyte in blood.

Neither the present assays as defined in claims 1 - 5 nor the test kits adapted to perform this assay (claims 6 - 12) are disclosed or suggested by the prior art documents referred to in the international search report.

The subject-matter is therefore novel and inventive, as required by Art. 33(2) and(3) PCT.

SECTION VIII:

2. Claim 4 extends beyond the scope of claim 1 to which it refers, as some of its features appear to be defined in more generic terms (compare "determining the **amount of blood**" in claim 4 to step ii of claim 1) than in claim 1, or are not reflected in the independent claim (determination of the interstitial fluid instead of blood volume in order to normalize the analyte concentration).

The dependent form has therefore not correctly used in claim 4. The deficiency causes uncertainty as to the actual scope of claims 1 and 4 (Art. 6 PCT).

3. The wording of claim 4 is, in addition, inconsistent with the actual disclosure of the present application.

According to the examples, the measurements of haemoglobin and glucose were carried out in a sample comprising both blood **and** interstitial fluid, while the wording of claim 4 conveys the impression that measurements were taken **either** in blood **or** on the interstitial fluid fraction.

Apart from the fact that it is not clear how these fluid fractions can be separated from each other, erythrocytes do not normally pass across the walls of the

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/IL99/00447

capillaries and are not expected to be found in the interstitial fluid.

This objection analogously applies to claim 10.

4. Contrary to claim 1, claim 6 which is directed to a kit fails to clarify the function of the blood component and thereby lacks an essential technical feature of the present invention.

According to the present invention, only selected blood components, i.e. those the concentration of which is rather constant and which thus can be correlated with the blood cell number or blood volume, are useful as analytes of the "normalizing" measurement (step ii).

CLAIMS:

1. A method for determining the level of an analyte in the blood of an individual comprising:
- 5 (i) obtaining a sample from said individual, said sample being a non-blood sample but containing blood components;
- (ii) determining the volume of blood in the obtained sample by measuring the level of a blood component in said samples;
- (iii) determining the amount of said analyte in the sample or in the blood cells present in said non-blood sample; and
- 10 (iv) calculating the level of said analyte in the blood of the tested individual based on the measurements in (iii) and (iv).
2. The method of Claim 1, wherein said blood component is hemoglobin.
- 15 3. The method of Claims 1 or 2, wherein said analyte is glucose.
4. A method according to Claim 1, wherein said non-blood sample is a sample of hair obtained from said individual, the method comprising:
- (i) obtaining a sample of hair from said individual;
- (ii) determining the amount of blood or interstitial fluid in said obtained sample and if necessary, correcting variations between different hair samples;
- 20 (iii) determining the level or concentration of said analyte in said blood or interstitial fluid and
- (iv) calculating the level of said analyte in the blood of the tested individual based on the measurements in (ii) and (iii).
- 25 5. A method according to claim 4 wherein before stage (ii) said blood or interstitial fluid are first extracted from the hair follicle of said obtained hair.
6. A kit for determining the level of an analyte in the blood of a tested individual comprising:
- 30

- (i) means for obtaining a sample from said individual, said sample being a non-blood sample but containing blood components;
 - (ii) means for measuring the level of a blood component in the sample;
 - 5 (iii) means for measuring the level of the tested analyte in the obtained sample;
 - (iv) means for calculating the level of the tested analyte in the blood of the tested individual on the basis of the measurements obtained in (ii) and (iii) above.
- 10 7. A kit according to Claim 6, further comprising means for separating said red blood cells from the sample.
8. A kit according to Claims 6 or 7, further comprising means for lysing said red blood cells.
9. A kit according to Claim 6, further comprising a test strip
- 15 incorporating reagents or structures necessary to carry out the measurement of the tested analyte and blood component and a instrument into which the test strip can be inserted into or to which the test strip may be connected; said instrument capable of detecting and analyzing a signal emitted by said test strips and optionally translating said signals into prevalent units..
- 20 10. A kit according to Claim 6, wherein the obtained body sample is a hair sample, said kit comprises the following:
- (i) hair removal means;
 - (ii) a suitable diluent in which the blood or interstitial fluid from the obtained hair is collected;
 - 25 (iii) means for the determination of the level of a blood component in the blood or interstitial fluid specimen;
 - (iv) means for determination of the level of said analyte in the blood or interstitial fluid specimen; and
 - (v) means for calculating the level of the tested analyte in the blood
 - 30 of the tested individual on the basis of the measurements obtained in (iii) and (iv) above.

11. A kit according to Claims 6-10, wherein the tested analyte is glucose.
12. A kit according to Claim 11, further comprising a metabolic inhibitor capable of preventing glucose utilization by living cells present in said
5 sample.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 119434.9 MM	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/IL99/00447	International filing date (day/month/year) 19/08/1999	Priority date (day/month/year) 21/08/1998
International Patent Classification (IPC) or national classification and IPC G01N33/50		
Applicant FISH, Falk		


1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 5 sheets, including this cover sheet.

☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

 These annexes consist of a total of 3 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand 20/03/2000	Date of completion of this report 19.10.2000
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Hoesel, H Telephone No. +49 89 2399 8693



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/IL99/00447

I. Basis of the report

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

Description, pages:

1-20 as originally filed

Claims, No.:

1-12 with telefax of 20/03/2000

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	1 - 12
	No:	Claims	
Inventive step (IS)	Yes:	Claims	1 - 12
	No:	Claims	
Industrial applicability (IA)	Yes:	Claims	1 - 12
	No:	Claims	

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/IL99/00447

2. Citations and explanations

see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

SECTION V:

1. The present assay method relies upon the finding that residual blood cells are contained in non-blood samples, and that the amount of analyte measured in these residual cells contained in a non-blood sample reflects the actual concentration of the analyte in blood.

Neither the present assays as defined in claims 1 - 5 nor the test kits adapted to perform this assay (claims 6 - 12) are disclosed or suggested by the prior art documents referred to in the international search report.

The subject-matter is therefore novel and inventive, as required by Art. 33(2) and(3) PCT.

SECTION VIII:

2. Claim 4 extends beyond the scope of claim 1 to which it refers, as some of its features appear to be defined in more generic terms (compare "determining the **amount of blood**" in claim 4 to step ii of claim 1) than in claim 1, or are not reflected in the independent claim (determination of the interstitial fluid instead of blood volume in order to normalize the analyte concentration).

The dependent form has therefore not correctly used in claim 4. The deficiency causes uncertainty as to the actual scope of claims 1 and 4 (Art. 6 PCT).

3. The wording of claim 4 is, in addition, inconsistent with the actual disclosure of the present application.

According to the examples, the measurements of haemoglobin and glucose were carried out in a sample comprising both blood **and** interstitial fluid, while the wording of claim 4 conveys the impression that measurements were taken **either** in blood **or** on the interstitial fluid fraction.

Apart from the fact that it is not clear how these fluid fractions can be separated from each other, erythrocytes do not normally pass across the walls of the

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/IL99/00447

capillaries and are not expected to be found in the interstitial fluid.

This objection analogously applies to claim 10.

4. Contrary to claim 1, claim 6 which is directed to a kit fails to clarify the function of the blood component and thereby lacks an essential technical feature of the present invention.

According to the present invention, only selected blood components, i.e. those the concentration of which is rather constant and which thus can be correlated with the blood cell number or blood volume, are useful as analytes of the "normalizing" measurement (step ii).

PATENT COOPERATION TREATY

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

REINHOLD COHN AND PARTNERS
P.O. Box 4060
61040 Tel-Aviv
ISRAEL

RECEIVED

22-10-2000

REINHOLD COHN & PARTNERS

23/10
SK

PCT

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL PRELIMINARY
EXAMINATION REPORT
(PCT Rule 71.1)

Date of mailing
(day/month/year) 19.10.2000

Applicant's or agent's file reference
119434.9 MM

IMPORTANT NOTIFICATION

International application No.
PCT/IL99/00447

International filing date (day/month/year)
19/08/1999

Priority date (day/month/year)
21/08/1998

Applicant
FISH, Falk

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/

 European Patent Office
D-80298 Munich
Tel. +49 89 2399 - 0 Tx: 523656 epmu d
Fax: +49 89 2399 - 4465

Authorized officer

Danti, B

Tel. +49 89 2399-8161



PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 119434.9 MM	FOR FURTHER ACTION <small>see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.</small>	
International application No. PCT/IL 99/ 00447	International filing date (day/month/year) 19/08/1999	(Earliest) Priority Date (day/month/year) 21/08/1998
Applicant FISH, Falk		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 2 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

a. With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing:

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

2. ☐ Certain claims were found unsearchable (See Box I).

3. ☐ Unity of invention is lacking (see Box II).

4. With regard to the title,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the abstract,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☒ None of the figures.

INTERNATIONAL SEARCH REPORT

International Application No.

CT/IL 99/00447

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 G01N33/50 G01N33/66 G01N33/72

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 91 13355 A (EPITOPE, INC.) 5 September 1991 (1991-09-05)	
A	WO 95 27205 A (EPITOPE, INC.) 12 October 1995 (1995-10-12)	
A	US 5 056 521 A (J. S. PARSONS ET AL.) 15 October 1991 (1991-10-15)	
A	US 5 362 307 A (R. GUY ET AL.) 8 November 1994 (1994-11-08) cited in the application	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"B" document member of the same patent family

Date of the actual completion of the international search

3 December 1999

Date of mailing of the international search report

17/12/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Griffith, G

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

T/IL 99/00447

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9113355	A	05-09-1991	AU 635997 B	08-04-1993
			US 5103836 A	14-04-1992
			AT 118095 T	15-02-1995
			AT 127229 T	15-09-1995
			AU 6996391 A	30-07-1992
			AU 653930 B	20-10-1994
			AU 7460991 A	18-09-1991
			CA 2023636 A	22-03-1991
			CA 2076754 A	29-08-1991
			DE 69016544 D	16-03-1995
			DE 69016544 T	08-06-1995
			DE 69112610 D	05-10-1995
			DE 69112610 T	08-02-1996
			EP 0418739 A	27-03-1991
			EP 0516746 A	09-12-1992
			ES 2070227 T	01-06-1995
			ES 2080944 T	16-02-1996
			GR 3018234 T	29-02-1996
			JP 3143435 A	19-06-1991
			JP 2535116 B	18-09-1996
			US 5335673 A	09-08-1994
			US 5479937 A	02-01-1996
			US 5573009 A	12-11-1992
			US 5234001 A	10-08-1993
			US 5339829 A	23-08-1993
			DK 418739 T	27-03-1995
			DK 516746 T	18-09-1995
			FI 923839 A	27-08-1992
			IE 74952 B	13-08-1997
			IE 73871 B	02-07-1997
			NO 923360 A	21-10-1992
			US 5830410 A	03-11-1998
WO 9527205	A	12-10-1995	US 5714341 A	03-02-1998
			AT 175274 T	15-01-1999
			AU 2197595 A	23-10-1995
			DE 69507019 D	11-02-1999
			EP 0753148 A	15-01-1997
US 5056521	A	15-10-1991	NONE	
US 5362307	A	08-11-1994	US 5730714 A	24-03-1998
			AT 129909 T	15-11-1995
			AU 639888 B	12-08-1993
			AU 3183889 A	25-08-1989
			DE 68924716 D	14-12-1995
			DE 68924716 T	04-07-1996
			DK 179390 A	28-07-1990
			EP 0326398 A	02-08-1989
			EP 0673622 A	27-09-1995
			ES 2085863 T	16-06-1996
			IE 63406 B	19-04-1995
			JP 2907342 B	21-06-1999
			JP 4502561 T	14-05-1992
			KR 9711449 B	11-07-1997
			PT 89560 A,B	10-11-1989
			WO 8906989 A	10-08-1989
			US 5279543 A	18-01-1994

CLAIMS:

1. A method for determining the level of an analyte in the blood of an individual comprising:
 - 5 (i) obtaining a sample from said individual, said sample being a non-blood sample but containing blood components;
 - (ii) determining the volume of blood in the obtained sample by measuring the level of a blood component in said samples;
 - (iii) determining the amount of said analyte in the sample or in the
10 blood cells present in said non-blood sample; and
 - (iv) calculating the level of said analyte in the blood of the tested individual based on the measurements in (iii) and (iv).
2. The method of Claim 1, wherein said blood component is hemoglobin.
- 15 3. The method of Claims 1 or 2, wherein said analyte is glucose.
4. A method according to any one of Claims 1-3, wherein said non-blood samples are urine or saliva samples, the method comprising:
 - (i) obtaining a urine or saliva sample from said individual;
 - (ii) measuring the level of said analyte in the red blood cells present
20 in said sample;
 - (iii) measuring the amount of a blood component in the red blood cells in said sample and on the basis of this measurement calculating the volume of blood cells or number of blood cells in said samples; and
 - 25 (iv) calculating the level of said analyte in the blood of the tested individual based on the measurements in (ii) and (iii).
5. A method according to Claim 4, wherein prior to measuring the level of said analyte in the red blood cells, said cells are first separated from the sample.

6. A method according to Claims 4 or 5, wherein a lysing agent capable of lysing said red blood cells is added to said obtained sample.

7. A method according to any one of Claims 4-6, wherein the sample obtained from the individual is a saliva sample.

5 8. A method according to Claim 7, wherein prior to obtaining said saliva sample, means are used to stimulate blood flow into the saliva of the individual from which the sample is obtained.

9. A method according to Claims 7 or 8, wherein means capable of removing or breaking down the mucinaceous materials present in said sample
10 are added to the saliva sample.

10. A method according to Claim 1, wherein said non-blood sample is a sample of hair obtained from said individual, the method comprising:

- (i) obtaining a sample of hair from said individual;
- (ii) determining the amount of blood or interstitial fluid in said
15 obtained sample and if necessary, correcting variations between different hair samples;
- (iii) determining the level or concentration of said analyte in said blood or interstitial fluid and
- (iv) calculating the level of said analyte in the blood of the tested
20 individual based on the measurements in (ii) and (iii).

11. A method according to claim 10 wherein before stage (ii) said blood or interstitial fluid are first extracted from the hair follicle of said obtained hair.

12. A kit for determining the level of an analyte in the blood of a
25 tested individual comprising:

- (i) means for obtaining a sample from said individual, said sample being a non-blood sample but containing blood components;
- (ii) means for measuring the level of a blood component in the sample;

(iii) means for measuring the level of the tested analyte in the obtained sample;

(iv) means for calculating the level of the tested analyte in the blood of the tested individual on the basis of the measurements obtained in (ii) and (iii) above.

5

13. A kit according to Claim 12, further comprising means for separating said red blood cells from the sample.

14. A kit according to Claims 12 or 13, further comprising means for lysing said red blood cells.

10

15. A kit according to Claim 12, further comprising a test strip incorporating reagents or structures necessary to carry out the measurement of the tested analyte and blood component and a instrument into which the test strip can be inserted into or to which the test strip may be connected; said instrument capable of detecting and analyzing a signal emitted by said test strips and optionally translating said signals into prevalent units.

15

16. A kit according to Claims 12-15, wherein the obtained body fluid sample is saliva further comprising means for stimulating blood flow into the saliva prior to obtaining of said sample.

20

17. A kit according to any one of Claims 12-16, wherein the obtained body fluid sample is saliva, said kit further comprising reagents and means capable of removing or breaking down the mucinaceous materials in said saliva sample.

18. A kit according to Claim 12, wherein the obtained body sample is a hair sample, said kit comprises the following:

25

(i) hair removal means;

(ii) a suitable diluent in which the blood or interstitial fluid from the obtained hair is collected;

(iii) means for the determination of the level of a blood component in the blood or interstitial fluid specimen;

(iv) means for determination of the level of said analyte in the blood or interstitial fluid specimen; and

(v) means for calculating the level of the tested analyte in the blood of the tested individual on the basis of the measurements obtained in (iii) and (iv) above.

5

19. A kit according to Claims 12-18, wherein the tested analyte is glucose.

20. A kit according to Claim 19, further comprising a metabolic inhibitor capable of preventing glucose utilization by living cells present in said

10 sample.

AMENDED CLAIMS

[received by the International Bureau on 13 February 2000 (13.02.00);
original claims 4-9 and 16-17 cancelled; original claims 10-15 and 18-20
renumbered as claims 4-9 and 10-12
other claims unchanged (3 pages)]

1. A method for determining the level of an analyte in the blood of an individual comprising:
 - 5 (i) obtaining a sample from said individual, said sample being a non-blood sample but containing blood components;
 - (ii) determining the volume of blood in the obtained sample by measuring the level of a blood component in said samples;
 - (iii) determining the amount of said analyte in the sample or in the
10 blood cells present in said non-blood sample; and
 - (iv) calculating the level of said analyte in the blood of the tested individual based on the measurements in (iii) and (iv).
2. The method of Claim 1, wherein said blood component is hemoglobin.
- 15 3. The method of Claims 1 or 2, wherein said analyte is glucose.
4. A method according to Claim 1, wherein said non-blood sample is a sample of hair obtained from said individual, the method comprising:
 - (i) obtaining a sample of hair from said individual;
 - (ii) determining the amount of blood or interstitial fluid in said
20 obtained sample and if necessary, correcting variations between different hair samples;
 - (iii) determining the level or concentration of said analyte in said blood or interstitial fluid and
 - (iv) calculating the level of said analyte in the blood of the tested
25 individual based on the measurements in (ii) and (iii).
5. A method according to claim 4 wherein before stage (ii) said blood or interstitial fluid are first extracted from the hair follicle of said obtained hair.
6. A kit for determining the level of an analyte in the blood of a
30 tested individual comprising:

- (i) means for obtaining a sample from said individual, said sample being a non-blood sample but containing blood components;
- (ii) means for measuring the level of a blood component in the sample;
- 5 (iii) means for measuring the level of the tested analyte in the obtained sample;
- (iv) means for calculating the level of the tested analyte in the blood of the tested individual on the basis of the measurements obtained in (ii) and (iii) above.

10 7. A kit according to Claim 6, further comprising means for separating said red blood cells from the sample.

8. A kit according to Claims 6 or 7, further comprising means for lysing said red blood cells.

9. A kit according to Claim 6, further comprising a test strip
15 incorporating reagents or structures necessary to carry out the measurement of the tested analyte and blood component and a instrument into which the test strip can be inserted into or to which the test strip may be connected; said instrument capable of detecting and analyzing a signal emitted by said test strips and optionally translating said signals into prevalent units..

20 10. A kit according to Claim 6, wherein the obtained body sample is a hair sample, said kit comprises the following:

- (i) hair removal means;
- (ii) a suitable diluent in which the blood or interstitial fluid from the obtained hair is collected;
- 25 (iii) means for the determination of the level of a blood component in the blood or interstitial fluid specimen;
- (iv) means for determination of the level of said analyte in the blood or interstitial fluid specimen; and
- (v) means for calculating the level of the tested analyte in the blood
30 of the tested individual on the basis of the measurements obtained in (iii) and (iv) above.

11. A kit according to Claims 6-10, wherein the tested analyte is glucose.
12. A kit according to Claim 11, further comprising a metabolic inhibitor capable of preventing glucose utilization by living cells present in said
5 sample.